Related references
Note: Only part of the references are listed.The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019
Yiyi Yao et al.
BIOMEDICAL ENGINEERING ONLINE (2022)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N. Allan et al.
HAEMATOLOGICA (2022)
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
Jeff P. Sharman et al.
LEUKEMIA (2022)
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
Eric Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak et al.
CANCERS (2022)
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Constantine S. Tam et al.
BLOOD ADVANCES (2022)
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Paul M. Barr et al.
BLOOD ADVANCES (2022)
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Constantine S. Tam et al.
HAEMATOLOGICA (2021)
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E. Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)
Shringi Sharma et al.
BLOOD (2021)
Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
Wojciech Jurczak et al.
BLOOD (2021)
SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Constantine S. Tam et al.
BLOOD (2021)
Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study
Jennifer A. Woyach et al.
BLOOD (2021)
Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies
Mazyar Shadman et al.
BLOOD (2021)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Jennifer A. Woyach et al.
BLOOD (2021)
First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr plus Ven) Versus Chlorambucil Plus Obinutuzumab (Clb plus O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study
Tahla Munir et al.
BLOOD (2021)
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results fro the Phase 1/2 BRUIN Study
Anthony R. Mato et al.
BLOOD (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Jacob D Soumerai et al.
Lancet Haematology (2021)
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
HAEMATOLOGICA (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman et al.
LEUKEMIA (2021)
Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations
Mariela Sivina et al.
BLOOD (2021)
Immune Therapy for Chronic Lymphocytic Leukemia Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
Mazyar Shadman et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm,-label, 2
Matthew S. Davids et al.
LANCET ONCOLOGY (2021)
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
William G. Wierda et al.
LEUKEMIA (2021)
Targeting Bruton's Tyrosine Kinase in CLL
Inhye E. Ahn et al.
FRONTIERS IN IMMUNOLOGY (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
Lorenzo Iovino et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Next-Generation Bruton Tyrosine Kinase Inhibitors
Deborah M. Stephens et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of Chronic Lymphocytic Leukemia
Jan A. Burger
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Inhye E. Ahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Nitin Jain et al.
BLOOD (2019)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Bruton Tyrosine Kinase Inhibitors Present and Future
Jan A. Burger
CANCER JOURNAL (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
Susan O'Brien et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies
Benjamin F. Tillman et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia
Valeria Spina et al.
BLOOD (2018)
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Preetesh Jain et al.
CLINICAL CANCER RESEARCH (2017)
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia
Yannick Le Bris et al.
HEMATOLOGICAL ONCOLOGY (2017)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions
Larry Mansouri et al.
SEMINARS IN CANCER BIOLOGY (2016)
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Susan M. O'Brien et al.
BLOOD (2016)
Complex Karyotype is a Stronger Predictor Than Del(17p) for an Inferior Outcome in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib-Based Regimens
Philip A. Thompson et al.
CANCER (2015)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Role of miR-15/16 in CLL
Y. Pekarsky et al.
CELL DEATH AND DIFFERENTIATION (2015)
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance
Rodrigo Jacamo et al.
BLOOD (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Share Paper
